Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy

Therapeutics and Clinical Risk Management

Volumn 8, Issue , 2012, Pages 377-384

  Rizzardini, Giuliano ^a   Bonfanti, Paolo ^b   Carenzi, Laura ^a   Coen, Massimo ^a   Orlando, Giovanna ^a   Di Matteo, Sergio ^c   Colombo, Giorgio L ^c,d  

^a UNIVERSITY OF MILAN   (Italy)

^b A MANZONI HOSPITAL   (Italy)

^c SAVE Studi Analisi Valutazioni Economiche   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

AIDS; Cost effectiveness; HAART antiretroviral therapy regimens; HIV; Markov model; QALYs; Quality adjusted life years; Single tablet regimen (STR)

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RITONAVIR; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MAJOR CLINICAL STUDY; MALE; MARKOV MODEL; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PUBLIC HOSPITAL; QUALITY OF LIFE; REVIEW; SENSITIVITY ANALYSIS; STATISTICAL MODEL; VALIDATION STUDY; VIREMIA;

EID: 84875317147     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S33674     Document Type: Review

References (33)

1. World Health Organisation. Global Summary of the HIV/AIDS Epidemic. Geneva, Switzerland: World Health Organization; 2009.
2. Steinbrook R. Providing antiretroviral therapy for HIV infection. N Engl J Med. 2001;344:844-846.
3. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44:990-997.
4. Mocroft A, Ledergerber B, Katlama C, et al; EUROSIDA study group. Decline in the AIDS and Death rates in the EUROSIDA study: an observational study. Lancet. 2003;362:22-29.
5. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-299.
6. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344:824-831.
7. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010;376:49-62.
8. Demography in figures [webpage on the Internet]. Demographic statistics. Rome: Istituto Nazionale di Statistica; 1999, 2008. Available from: http://www.demo.istat.it/index_e.html. Accessed July 10, 2011.
9. Istituto Superiore di Sanità [Institute of Health]. Notiziario dell'Istituto Superiore di Sanità 2010. 2010;23(4Suppl1). Available from: http://www.iss.it/publ/noti/cont.php?id=2449&lang=1&tipo=4&anno=2010. Accessed June 10, 2012. Italian.
10. Istituto Superiore di Sanità [Institute of Health]. Aggiornamento delle nuove diagnosi di infezione da HIV e dei casi di AIDS in Italia [Update of new diagnoses of HIV infection and AIDS cases in Italy]. Available from: http://www.iss.it/binary/pres/cont/dic2008.1228391047.pdf. Accessed November 13, 2011. Italian.
11. Lombardy Region. The Social and Healthcare Plan, No 937/2010. Available from: http://www.sanita.regione.lombardia.it/cs/Satellite?c=Redazionale_P&childpagename=DG_Sanita%2FDetail&cid=1213398553292&packedargs=NoSlotForSitePlan%3Dtrue%26menu-to-render%3D1213277443740&pagename=DG_SANWrapper. Accessed June 10, 2012. Italian.
12. Lombardy Region. Decree n. 7485 05 August 2011. Approvazione del documento avente peroggetto Percorso Diagnostico Terapeutico (PDT) per il paziente affetto da malattia HIV/AIDS [Therapeutic and Diagnostic Path (PDT) for the patient with HIV disease]. Available from: http://www.sanita.regione.lombardia.it/cs/Satellite?c=Page&childpagename=DG_Sanita/Page/NormativaDetail&pagename=DG_SANWrapper&cid=1213275902673&keyid=3520. Accessed June 10, 2012. Italian.
13. Rizzardini G, Restelli U, Bonfanti P, et al. The cost of HIV disease in Northern Italy: the payer's perspective. J Acquir Immune Defic Syndr. 2011;57:211-217.
14. Colombo GL, Colangeli V, Di Biagio A, Di Matteo S, Viscoli C, Viale P. Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. Clinicoecon Outcomes Res. 2011;3:197-205.
15. Simpson KN, Strassburger A, Jones WJ, Dietz B, Rajagopalan R. Comparison of Markov model and discrete-event simulation techniques for HIV. Pharmacoeconomics. 2009;27:159-165.
16. Simpson KN, Luo MP, Chumney E, et al. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV irtfection. HIV Clin Trials. 2004;5:294-304.
17. EuroQol Group. EQ-5D. Available from: http://www.euroqol.org. Accessed February 20, 2011.
18. Ravasio R. Analisi di costo-efficacia di entrcitabina/tenofovir disoproxil più efavirenz rispetto ad altri regimi antiretrovirali nel trattamento di prima linea di pazienti affetti da HIV [Cost-effectiveness analysis of emtricitabine/tenofovir disoproxil plus efavirenz versus other antiretroviral regimes in first line treatment of HIV patients]. Giornale Italiano di Health Technology Assessement. 2010;3(1):1-11. Italian.
19. AIFA Italian Drug Agency. Negoziazione e rimborsabilitá [Negotiation and reimbursement]. Available from: http://www.agenziafarmaco.gov.it/it/content/negoziazione-e-rimborsabilit%C3%A0. Accessed November 13, 2011. Italian.
20. TimeSeries Italian Historical Statistical Repository [webpage on the Internet]. Rome: Istituto Nazionale di Statistica; nd. Available from: http://timeseries.istat.it. Accessed November 10, 2011.
21. AIES Italian Health Economics Association. Associazione Italiana di Economia Sanitaria. Italian Guidelines proposal on how to conduct economic evaluation studies of health programs. Pharmacoeconomics - Italian Research Articles. 2009;11:83-93.
22. Regione Emilia-Romagna. Lo stato dell'infezione da HIV/AIDS in emiliaromagna Aggiornamento sull'epidemia e primi risultati del sistema di sorveglianza dell'infezione da HIV al 31/12/2009 [Epidemiologic survey on HIV/AIDS, 31/12/2009]. Available from: http://www.helpaids.it/flex/cm/pages/ServeBLOB.php/L/IT/IDPagina/50. Accessed November 10, 2011. Italian.
23. Jonsson B. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics. 2004;22(Suppl 4):5-10.
24. Lucioni C, Ravasio R. Come valutare i risultati di uno studio farmacoeconomico? [How to evaluate the results of a pharmacoeconomic study?] PharmacoEconomics - Italian Research Articles. 2004;3:121-130. Italian.
25. Messori A, Santarlasci B, Trippoli S, Vaiani M. Controvalore economico del farmaco e beneficio clinico: Stato dell'arte della metodologia e applicazione di un algoritmo farmacoeconomico [Clinical benefit and economic value: methodology and an economic application]. Pharmaco Economics - Italian Research Articles. 2003;5:53-67. Italian.
26. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010;4:115-125.
27. D'Arminio Monforte A, Lepri AC, Rezza G, et al; I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. AIDS. 2000;14:499-507.
28. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
29. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181-1183.
30. Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50:529-536.
31. Antinori A, Cozzi-Lepri A, Ammassari A, et al. Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir Ther. 2004;9:291-296.
32. Colombo GL, Gaeta GB, Viganò M, et al. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clinicoecon Outcomes Res. 2011;3:37-46.
33. Johnson LF, White PJ. A review of mathematical models of HIV/AIDS interventions and their implications for policy. Sex Transm Infect. 2011;87(7):629-634.